Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study

. Author manuscript; available in PMC: 2022 Jun 22.

Published in final edited form as: Eur Respir J. 2022 Apr 21;59(4):2100905. doi: 10.1183/13993003.00905-2021

Figure 3. Difference in IL-6 concentrations between tuberculosis patients with and without unfavorable treatment outcomes, and associated area under the curve (AUC) among all participants (Panel A) and restricted to patients with diabetes only (Panel B) in the Indian external validation cohort.